Lizdany Florez-Alvarez
Overview
Explore the profile of Lizdany Florez-Alvarez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naranjo-Covo M, Rincon-Tabares D, Florez-Alvarez L, Hernandez J, Zapata-Builes W
Immun Inflamm Dis
. 2025 Feb;
13(2):e70138.
PMID: 39998960
Introduction: Although repeated exposure to HIV-1 can result in infection, some individuals remain seronegative without clinical or serologic evidence of infection; these individuals are known as HIV-1-exposed seronegative individuals. This...
2.
Reinke P, de Souza E, Gunther S, Falke S, Lieske J, Ewert W, et al.
Commun Biol
. 2023 Oct;
6(1):1058.
PMID: 37853179
Several drug screening campaigns identified Calpeptin as a drug candidate against SARS-CoV-2. Initially reported to target the viral main protease (M), its moderate activity in M inhibition assays hints at...
3.
Rincon D, Florez-Alvarez L, Taborda N, Hernandez J, Rugeles M, Zapata-Builes W
Sci Rep
. 2023 Oct;
13(1):16766.
PMID: 37798386
Despite being under constant exposure to HIV-1, some individuals do not show serological or clinical evidence of infection and are known as HESN (HIV-Exposed Seronegative). Multiple studies in different HESN...
4.
Zapata-Cardona M, Florez-Alvarez L, Gomez-Gallego D, Moncada-Diaz M, Hernandez J, Diaz F, et al.
Iran J Microbiol
. 2023 May;
14(3):291-299.
PMID: 37124861
Background And Objectives: SARS-CoV-2 variants of concern (VOC) and interest (VOI) pose a significant threat to public health because the rapid change in the SARS-CoV-2 genome can alter viral phenotypes...
5.
In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach
Zapata-Cardona M, Florez-Alvarez L, Guerra-Sandoval A, Chvatal-Medina M, Guerra-Almonacid C, Hincapie-Garcia J, et al.
AIMS Microbiol
. 2023 Mar;
9(1):20-40.
PMID: 36891537
Background: Drug repurposing is a valuable strategy for rapidly developing drugs for treating COVID-19. This study aimed to evaluate the antiviral effect of six antiretrovirals against SARS-CoV-2 in vitro and...
6.
Zapata-Cardona M, Florez-Alvarez L, Lopera T, Chvatal-Medina M, Zapata-Builes W, Diaz F, et al.
Front Immunol
. 2023 Jan;
13:1102384.
PMID: 36618393
The emergence of the Omicron variant has generated concerns about the efficacy of COVID-19 vaccines. We evaluated the serum neutralizing activity of antibodies against the Omicron (lineage BA.1.1) by plaque...
7.
Ossa-Giraldo A, Blanquiceth Y, Florez-Alvarez L, Contreras-Ramirez K, Rojas M, Hernandez J, et al.
PLoS One
. 2022 Dec;
17(12):e0277120.
PMID: 36480500
Human immunodeficiency virus (HIV) infection still represents a major public health problem worldwide, and its vaccine remains elusive. The study of HIV-exposed seronegative individuals (HESN) brings important information about the...
8.
Florez-Alvarez L, de Souza E, Botosso V, de Oliveira D, Ho P, Taborda C, et al.
Front Microbiol
. 2022 Nov;
13:1040093.
PMID: 36386719
Hemorrhagic fever viruses (HFVs) pose a threat to global public health owing to the emergence and re-emergence of highly fatal diseases. Viral hemorrhagic fevers (VHFs) caused by these viruses are...
9.
Uruena C, Ballesteros-Ramirez R, Gomez-Cadena A, Barreto A, Prieto K, Quijano S, et al.
Front Med (Lausanne)
. 2022 Sep;
9:991873.
PMID: 36160152
Background: It has been proposed that polyphenols can be used in the development of new therapies against COVID-19, given their ability to interfere with the adsorption and entrance processes of...
10.
Patarroyo M, Patarroyo M, Pabon L, Alba M, Bermudez A, Rugeles M, et al.
Front Immunol
. 2022 Jun;
13:859905.
PMID: 35693819
Fifty ~20-amino acid (aa)-long peptides were selected from functionally relevant SARS-CoV-2 S, M, and E proteins for trial and another 53 common ones, plus some new ones derived from the...